Kymera Completes Enrollment
Kymera Therapeutics completes enrollment in global BROADEN2 Phase 2b trial of KT-621 for atopic dermatitis treatment
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
KYMR Completes Enrollment
Kymera Therapeutics completes enrollment in the Phase 2b BROADEN2 trial of KT-621 in atopic dermatitis with topline data expected by year-end 2026